Frantz et al.'s study pointed out that deletion of the NF-κB subunit p50 in mouse improved early survival and reduces left ventricular dilatation after MI; these findings indicate that NF-κB may therefore be an attractive target for HF treatment [107]. Here, NFKB1 is linked to myocardial infarction.